NovaBridge Biosciences (NBP) has a current Price-to-Book (P/B) ratio of 1.90. Compared to its 3-year average P/B ratio of 1.89, the current P/B ratio is approximately 0.40% higher. Relative to its 5-year average P/B ratio of 1.89, the current P/B ratio is about 0.40% higher. NovaBridge Biosciences (NBP) has a Forward Free Cash Flow (FCF) yield of approximately -3.45%. Compared to its 3-year average FCF yield of 1.86%, the current FCF yield is approximately -285.51% lower. Relative to its 5-year average FCF yield of 1.86%, the current FCF yield is about -285.51% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for NBP competitors is 3.68, providing a benchmark for relative valuation. NovaBridge Biosciences Corp (NBP.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of NBP increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of NBP in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is NBP currently overvalued or undervalued?

What is NovaBridge Biosciences (NBP) fair value?

NBP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of NovaBridge Biosciences (NBP) is between to according to relative valuation method.

How does NBP's valuation metrics compare to the industry average?

The average P/S ratio for NBP's competitors is 3.68, providing a benchmark for relative valuation. NovaBridge Biosciences Corp (NBP) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for NovaBridge Biosciences (NBP) as of Mar 03 2026?

As of Mar 03 2026, NovaBridge Biosciences (NBP) has a P/B ratio of 1.90. This indicates that the market values NBP at 1.90 times its book value.

What is the current FCF Yield for NovaBridge Biosciences (NBP) as of Mar 03 2026?

As of Mar 03 2026, NovaBridge Biosciences (NBP) has a FCF Yield of -3.45%. This means that for every dollar of NovaBridge Biosciences's market capitalization, the company generates -3.45 cents in free cash flow.

What is the current Forward P/E ratio for NovaBridge Biosciences (NBP) as of Mar 03 2026?

As of Mar 03 2026, NovaBridge Biosciences (NBP) has a Forward P/E ratio of -4.62. This means the market is willing to pay $-4.62 for every dollar of NovaBridge Biosciences's expected earnings over the next 12 months.

What is the current Forward P/S ratio for NovaBridge Biosciences (NBP) as of Mar 03 2026?

As of Mar 03 2026, NovaBridge Biosciences (NBP) has a Forward P/S ratio of 0.00. This means the market is valuing NBP at $0.00 for every dollar of expected revenue over the next 12 months.

NBP Valuation